Flexible clinical solutions for biotech
Your milestones. Your needs. Your team.
Connecting experience, data and technology to optimize your clinical trial
Innovative emerging biopharma and biotech companies are driving the drug development pipeline; competition for funding and resources is fierce. IQVIA Biotech delivers flexible clinical development solutions designed for the specific needs of biotech companies.
When you partner with our clinical development team you gain expertise from more than two decades of running clinical trials exclusively for biotech companies, plus access to IQVIA's unparalleled data and technology. We understand the unique challenges and opportunities you face. From drug development strategy to trial design and execution, we draw on this experience to put together the right solution, and the right team, for you.
IQVIA Biotech is here to help you succeed
THE LATEST FROM IQVIA BIOTECH
Emerging Biopharma's Contribution to Innovation
The report provides clarity on the current landscape of EBP companies and their emerging product pipelines, as well as associated clinical trial activity and levels of trial success. In addition, the report focuses on the financial deals, technology and approaches to enable and accelerate these companies' efforts, profiling the drugs these companies have launched or originated, and an assessment of the success of launches in recent years including nuances beyond simply sales uptake.
Advancing Asset Value Across Milestones
On the surface, your milestones may look the same as large pharma's. But we know that you face very different questions along your journey. The answers to those questions can impact not only your asset's probability of success, but that of your overall company.
For emerging biopharma and biotech companies to excel in today's challenging environment, it's critical to leverage a deep understanding of the therapeutic area, regulatory pathways, patient profiles and market dynamics throughout the journey from clinical to commercial. Learn more about our comprehensive suite of end-to-end solutions, Asset Maximizer, delivered by experts dedicated to you, to help get your breakthrough to patients, faster.
Institute Reports